Advertisement

Management of Anticoagulation with Impella® Percutaneous Ventricular Assist Devices and Review of New Literature

  • Luma Succar
  • Elisabeth M. Sulaica
  • Kevin R. Donahue
  • Matthew A. WanatEmail author
Article
  • 8 Downloads

Abstract

Cardiogenic shock is a life-threatening condition that may occur secondary to a variety of cardiac conditions, and may require temporary support with percutaneous ventricular devices like the Impella®. Anticoagulation in patients with Impella® devices can often be complicated due to unpredictable purge flow rates, pre-existing coagulopathy, or heparin allergies. The purpose of this article is to discuss the various options for anticoagulation in the setting of Impella®. The article will also describe recent updates (2014–current) in literature surrounding anticoagulation therapy for Impella® devices. At total of 228 articles were initially obtained through the PubMed search, with inclusion of 6 articles. A total of 51 patients had data in the six studies that were included in the review. Heparin for anticoagulation in the purge solution, at two different dextrose concentrations (5% and 20%), was associated with similar therapeutic activated partial thromboplastin time rates, thrombotic and bleeding events. One case series described the use of argatroban in the purge solution for anticoagulation in two patients with suspected heparin-induced thrombocytopenia, without bleeding or thrombotic complications. Pump thrombosis was not reported in any of the six studies. Anticoagulation in the setting of mechanical circulatory support devices is a challenging aspect of critical care. Institutions should have set protocols that clearly define the options for anticoagulation. Future studies that look at longer durations of support and possible operation of the Impella® device with a heparin-free purge solution are needed.

Keywords

Anticoagulation Ventricular assist device Heparin Thrombosis Bleeding 

Notes

References

  1. 1.
    Ko B, Drakos SG (2015) Referral and management of cardiogenic shock 2015. Am J Cardiol. http://www.acc.org/latest-in-cardiology/articles/2014/12/23/08/57/referall-and-management-of-cardiogenic-shock-expert-analysis. Expert analysis. Accessed 9 Oct 2018
  2. 2.
    Nativi-Nicolau J, Selzman CH, Fang JC, Stehlik J (2014) Pharmacologic therapies for acute cardiogenic shock. Curr Opin Cardiol 29(3):250–257CrossRefGoogle Scholar
  3. 3.
    O’gara PT, Kushner FG, Ascheim DD et al (2012) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127(4)Google Scholar
  4. 4.
    Rihal CS, Naidu SS, Givertz MM et al (2015) 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. J Am Coll Cardiol 85(7):1112–1114Google Scholar
  5. 5.
    Abiomed® (2018) Impella® ventricular support systems for use during cardiogenic shock and high-risk PCI instructions for use and clinical reference manual.Google Scholar
  6. 6.
    Jennings DL, Nemerovski CW, Kalus JS (2013) Effective anticoagulation for a percutaneous ventricular assist device using a heparin-based purge solution. Ann Pharmacother 47(10):1364–1367CrossRefGoogle Scholar
  7. 7.
    Burzotta F, Trani C, Doshi SN et al (2015) Impella ventricular support in clinical practice: collaborative viewpoint from a European expert user group. Int J Cardiol 201:684–691CrossRefGoogle Scholar
  8. 8.
  9. 9.
    Fitousis K, Klasek R, Mason PE, Masud F (2016) Evaluation of a pharmacy managed heparin protocol for extracorporeal membrane oxygenation patients. Perfusion.  https://doi.org/10.1177/0267659116678057 Google Scholar
  10. 10.
    Jennings DL, Nemerovski CW, Khandelwal A (2010) Extended use of a percutaneous left-ventricular assist device without a heparin-based purge solution. Am J Health-Syst Pharm 67(21):1825–1828CrossRefGoogle Scholar
  11. 11.
    Seyfarth M, Sibbing D, Bauer I et al (2008) A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intraaortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52(19):1584–1588CrossRefGoogle Scholar
  12. 12.
    Castillo-Sang MA, Prasad SM, Singh J et al (2013) Thirty-five day Impella 5.0 support via right axillary side graft cannulation for acute cardiogenic shock. Innovations (Phila) 8(4):307–309Google Scholar
  13. 13.
    Institute for Safe Medication Practices (ISMP). ISMP list of high-alert medications in acute care settings. http://www.ismp.org/Tools/institutionalhighAlert.asp. Accessed 28 Feb 2017
  14. 14.
    Institute for Safe Medication Practices (ISMP). ISMP’s guidelines for standard order sets. https://www.ismp.org/tools/guidelines/StandardOrderSets.asp. Accessed 28 Feb 2017
  15. 15.
    Institute for Safe Medication Practices (ISMP). High-alert medication feature: anticoagulant safety takes center stage in 2007. https://www.ismp.org/newsletters/acutecare/articles/20070111.asp
  16. 16.
    Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210CrossRefGoogle Scholar
  17. 17.
    Sieg A, Mardis BA, Mardis CR et al (2015) Developing an anti-Xa-based anticoagulation protocol for patients with percutaneous ventricular assist devices. ASAIO J 61(5):502–508CrossRefGoogle Scholar
  18. 18.
    Laliberte B, Reed BN (2017) Use of an argatroban-based purge solution in a percutaneous ventricular assist device. Am J Health-Syst Pharm 74(9):e163–e169CrossRefGoogle Scholar
  19. 19.
    Blum EC, Martz CR, Selektor Y, Nemeh H, Smith ZR, To L (2018) Anticoagulation of percutaneous ventricular assist device using argatroban-based purge solution: a case series. J Pharm Pract 31(5):514–518CrossRefGoogle Scholar
  20. 20.
    Dietrich JN, Kazmi H (2018) Bleeding risks in patients on percutaneous ventricular assist devices receiving two different dextrose concentrations of heparinized purge solution: a case series. J Pharm PractGoogle Scholar
  21. 21.
    Lee MC, Peters C, Rai N, Safani M, Thomas GS (2018) Unfractionated heaprin protocol during percutaneous left ventricular mechanical circulatory (impella) support. J Cardiovasc Pharmacol Ther.  https://doi.org/10.1177/1074248418816322 Google Scholar
  22. 22.
    Newsome AS, Taylor A, Garner S (2019) Anticoagulation of a percutaneous left ventricular assist device using a low-dose heparin purge solution protocol: a case series. J Pharm Pract.  https://doi.org/10.1177/0897190018822105 Google Scholar
  23. 23.
    Maini B, Moses J, Dixon S et al (2016) TCT-24 Global cVAD Registry: a global initiative in percutaneous circulatory support from the cVAD Steering Committee on behalf of all cVAD Investigators. J Am Coll Cardiol 68(18)Google Scholar
  24. 24.
    Vetrovec GW, Anderson M, Schreiber T et al (2018) The cVAD registry for percutaneous temporary hemodynamic support: a prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. Am Heart J 199:115–121CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PharmacyHouston Methodist HospitalHoustonUSA
  2. 2.Department of Pharmacy Practice and Translational ResearchUniversity of Houston College of PharmacyHoustonUSA

Personalised recommendations